Pullulan-Based Spray-Dried Mucoadhesive Microparticles for Sustained Oromucosal Drug Delivery

Ting Liu1, Xiang Gong2, Yang Cai1

  • 1College of Stomatology, Guizhou Medical University, Guiyang 550004, China.

Pharmaceutics
|April 27, 2024
PubMed

Insights

New pullulan microparticles offer enhanced oral drug delivery. These mucoadhesive particles provide sustained release and prolonged residence time for treating local oral diseases.

Area of Science:

  • Pharmaceutical Technology
  • Biomaterials Science
  • Drug Delivery Systems

Background:

  • Mucoadhesive microparticles enhance oromucosal drug delivery by increasing mucosal contact and residence time.
  • Benzydamine hydrochloride (BZH) is a drug used for local oral conditions.

Purpose of the Study:

  • To develop and characterize mucoadhesive spray-dried microparticles of pullulan for oromucosal delivery of benzydamine hydrochloride (BZH).
  • To evaluate the drug release profile, mucoadhesion, and retention of BZH-loaded pullulan microparticles on oral mucosal membranes.

Main Methods:

  • Mucoadhesive microparticles were prepared using pullulan and benzydamine hydrochloride (BZH) via spray-drying.
  • Particle size, angle of repose, drug release kinetics, and mucoadhesion were analyzed.
  • Retention of microencapsulated gold nanoparticle probes on mucosal membranes was quantified.

Main Results:

  • The BZH-pullulan microparticles exhibited a mean size of <25 μm and favorable flow properties (angle of repose 25.8-36.6°).
  • Pullulan significantly extended BZH release (>180 min), approximately nine times longer than reported for chitosan.
  • Mucoadhesion studies showed retention of up to 78.8% w/w of microencapsulated probes on the mucosal membrane.

Conclusions:

  • BZH-pullulan microparticles demonstrate significant potential for oromucosal drug delivery.
  • The formulation provides sustained drug release and prolonged in situ residence time, suitable for treating local oral diseases.
  • Pullulan's mucoadhesive properties contribute to enhanced drug delivery efficacy.

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
465
Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
428
Factors Affecting Dissolution: Particle Size and Effective Surface Area01:23

Factors Affecting Dissolution: Particle Size and Effective Surface Area

Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
823
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
418
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
338
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
234